Skip to main content
ACHV
NASDAQ Life Sciences

AchieveRx Posts Q3 2026 Results: $201.5M Cash, NDA Resubmission on Track for Q4

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$6.71
Mkt Cap
$697.679M
52W Low
$2.62
52W High
$8.64
52W Position info
156% above low
Off High info
22% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ACHV has more than doubled off its 52-week low of $2.62.

Summary

AchieveRx reported a $12.1M Q3 2026 net loss but ended September with $201.5M in cash and securities, and said its cytisinicline NDA resubmission remains on track for Q4 2026 with potential approval by end-Q2 2027.


Key Events · Earnings and Guidance · ACHV

  • Q3 Loss Narrower, Cash Builds

    Q3 2026 net loss of $12.1M vs $14.4M a year ago; cash, equivalents and marketable securities rose to $201.5M from $187.3M at June 30 on warrant exercise proceeds.

  • NDA Resubmission on Track

    Three commercial-scale stability batches completed at Adare; cytisinicline NDA resubmission guided to Q4 2026, with potential FDA approval by end of Q2 2027.

  • 52-Week ORCA-OL Data Presented

    Abstinence rose from 25.5% at Weeks 9-12 to 31.2% at Weeks 49-52; 39.4% of cytisinicline-naive participants quit by end of treatment, with no new safety signals.

  • Rebrand and Ticker Change

    Company now does business as AchieveRx, The Quit Company, and trades on Nasdaq under QUIT as of November 9, 2026.


Analysis · ACHV · Life Sciences

The quarter itself was a loss ($12.1M), but the balance sheet is the story: $201.5M in cash and securities at September 30, up from $187.3M at June 30 because warrant holders exercised. That funds the cytisinicline NDA resubmission, now guided to Q4 2026, with potential FDA approval by the end of Q2 2027. The nine-month net loss of $97.0M is far wider than last year's $40.0M, largely reflecting the prior warrant fair-value swings and a heavier G&A build-out for launch. New 52-week ORCA-OL data (31.2% abstinence at Weeks 49-52) supports the filing package. The main risk remains regulatory: the prior Complete Response Letter and the Sopharma arbitration are still unresolved, and approval timing depends on the FDA accepting the resubmission.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACHV was trading at $6.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $697.7M. The 52-week trading range was $2.62 to $8.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACHV - Latest Insights

ACHV
Nov 10, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.71
Real-time Price: $6.71 info
Change: $0 (0%) info
Market Cap: $697.679M info
ACHV
Aug 11, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.77
Real-time Price: $6.71 info
Change: -$0.060 (-0.89%) info
Market Cap: $697.679M info
ACHV
Aug 11, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.77
Real-time Price: $6.71 info
Change: -$0.060 (-0.89%) info
Market Cap: $697.679M info
ACHV
Aug 11, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.52
Real-time Price: $6.71 info
Change: +$0.190 (+3%) info
Market Cap: $697.679M info
ACHV
Jul 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $6.71 info
Change: +$0.250 (+4%) info
Market Cap: $697.679M info